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On 2 April 2014, the European Parliament approved the new
European Union Clinical Trials Regulation.1 This regulation
will replace the Clinical Trials Directive, which has failed to
achieve its goal of simplifying the scientific and ethical review
of clinical trials in the EU.2 3 Unlike the directive, the regulation
has binding legal force in all EU member states. Important
innovations include a central database and a partly coordinated
review system. Both of these steps could help simplify the
review system and improve the quality of assessments.
However, when it drafted the regulation, quality improvement
did not seem to be the European Commission’s main concern.
Despite serious criticisms and several adjustments, the approved
document may still impair, rather than improve, the quality of
the ethical review of trial protocols.4-9 This puts the protection
of European research subjects at risk.
Before discussing our two main concerns, we need to explain
the new review system. Currently, all member states assess the
request for authorisation of a multinational clinical trial
independently of one another. To simplify and speed up
authorisation, the European Commission has decided that the
risk-benefit assessment (and the preceding scientific assessment)
should be performed in a coordinated manner.5 9 With this in
mind, sponsors propose one member state to be the reporting
one, and this member state makes the final decision on the
risk-benefit assessment. The other member states are asked for
their input, but within a very tight time frame. Their main task
is to assess the ethical and local aspects, such as the informed
consent material, the investigators’ qualifications, and the
suitability of the trial site, for their own territory. Thus, two
types of assessment run in parallel: the coordinated risk-benefit
assessment (by the reporting member state, binding on all
member states), and the assessment of the ethical and local
aspects mentioned above (by all member states acting
individually).
We approve the idea of coordinating the assessment of
multinational clinical trials. However, in the case of such
centralised judgments, the quality of these judgments should
be guaranteed. This is not the case.
We are mostly worried about the risk-benefit assessment being
taken out of the ethical domain. The European Commission
fails to acknowledge that this assessment is widely regarded as
a crucial part of ethical review.10As a result, the regulation does
not require input from an ethics committee.9 This is worrying
because the purpose of ethics committees is to focus on the
protection of potential research subjects. This perspective is
indispensable when the risks of harm and potential benefits of
a clinical trial are being assessed. It is worth noting that studies
may be ethically unacceptable, despite having a scientifically
favourable harm-benefit balance, if the research question could
be answered with fewer risks or burdens for the research
subjects.
Furthermore, some studies have a favourable harm-benefit
balance because of the expected benefits for society but are not
expected to benefit the research subjects themselves. Such
studies should be evaluated very carefully, particularly when
they involve children or others who are considered unable to
provide informed consent.10 The regulation provides guidelines
for research in these groups, but applying these guidelines
appropriately requires specific ethical expertise.9 Ideally, a
multidisciplinary committee with wide ethical expertise should
critically assess the risks and potential benefits and demand
changes in the design when needed.
A complicating factor is that sponsors are free to choose the
reporting member state. This might tempt sponsors to choose
member states that are known for their less onerous assessments.
Thus, when aiming for high quality review, the question of
which body should perform the risk-benefit assessment cannot
be left to the member states’ own discretion.
Our second concern relates to the quality of the ethics
committees. During the first public consultation round many
respondents asked for quality standards and an accreditation
system for these committees,4 but the European Commission
has ducked this request—a truly missed opportunity. This is
because even though ethical matters are regarded as a national
affair, the new regulation would provide a great opportunity for
improving the widely varying quality of the EU’s ethics
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committees by setting clear quality standards.11 Leaving these
committees just as diverse as before means that European
citizens of different member states cannot rely on the same level
of protection. Moreover, if ethics committees are also involved
in the coordinated risk-benefit assessment, which we have just
argued for, every opportunity to improve their quality should
be taken. The judgment of the ethics committee of the reporting
member state will then cover the protection of the research
subjects in all member states.
We recognise that it will be difficult to make substantial changes
to the new regulation now that it has been approved. However,
it is wrong to rush through a system that is clearly inadequate.
European research subjects deserve a clinical trials regulation
that has a sound ethical basis. Therefore, we recommend that
this new legislation is adjusted before coming into force.
In practical terms, we recommend that the ethics committee of
the reporting member state should be assigned as the key figure
in an integrated risk-benefit assessment system. In addition, this
committee should be allowed enough time to take scientific
advice from experts and to cooperate effectively with the ethics
committees of the other member states. Lastly, a quality and
accreditation system should be established for all ethics
committees so that all trials are reviewed by competent
committees.
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